Market Cap
$97.4B
GSK
GSK plc
$47.01 ▼ -0.35%
Prev close $47.18Market cap$97.4B
12-mo target$59.58 (+26.7%)
High Impact Filing (7/10)29 New Institutional Positions21 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on GSK right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Inst. Holders
50 funds
Inst. Value
$14.5B
Inst. Activity
29 buys / 21 sells
Social Sentiment
82° Bullish
SEC Reports
20
Price chart 30d -6.8%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 short_volume
Sep 15, 2026 SEC Short Volume: GSK — 62.6% short (0.6M / 1.0M)
Short: 603,019 | Exempt: 0 | TRF Vol: 964,053 | Short Ratio: 62.6% | Off-exchange volume (dark pool
GSK announced an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for multiple myeloma fr
6-K — Impact 5/10
GSK announced positive overall survival data from the ARTEMIS-008 Phase III trial of Ris-Rez (risvutatug rezetecan) in r
6-K — Impact 7/10
GSK announced positive registrational data from the ARROS-1 trial evaluating Jideytro (zidesamtinib) in first-line ROS1-
6-K — Impact 7/10
Jun 30, 2026 Inst.
MORGAN STANLEY — TRIM
7,657,562 shares ($401.4M)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — TRIM
6,371,442 shares ($334.0M)
Jun 17, 2026 Event
UTEBZI
Original Approval — Type 1 - New Molecular Entity — TABLET
Jun 16, 2026 Event
GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC v. Pfizer Inc., Pharmacia & Upjohn Co. LLC, BioNTech SE, BioNTech Manufacturing GmbH, and BioNTech US Inc.; GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC v. Moderna, Inc., ModernaTX, Inc., and Moderna US, Inc.
Court ruling from District Court, D. Delaware. Docket: 1:24-cv-00512
Analyst ratings buy % -2.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Jan 6, 2026 | Barclays | DOWNGRADE | Underweight | 54% |
| Nov 12, 2024 | Jefferies | DOWNGRADE | Hold | 53% |
| Oct 31, 2024 | Guggenheim | DOWNGRADE | Neutral | 52% |
| Jul 8, 2024 | UBS | DOWNGRADE | Neutral | 55% |
| Jul 2, 2024 | Jefferies | MAINTAIN | Buy | 53% |
| May 30, 2024 | Goldman Sachs | INITIATE | Neutral | 54% |
| Mar 4, 2024 | Guggenheim | UPGRADE | Buy | 52% |
| Jan 23, 2024 | Morgan Stanley | INITIATE | Equal-Weight | 55% |
| Jan 3, 2024 | Jefferies | UPGRADE | Buy | 53% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 8 | 15 | 3 | 0 | 44% | |
| Aug 1, 2026 | 6 | 8 | 15 | 3 | 0 | 44% | |
| Jul 1, 2026 | 5 | 8 | 13 | 4 | 0 | 43% | |
| Jun 1, 2026 | 6 | 8 | 14 | 4 | 0 | 44% | |
| May 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Apr 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Mar 1, 2026 | 5 | 8 | 15 | 4 | 0 | 41% | |
| Feb 1, 2026 | 6 | 8 | 14 | 4 | 0 | 44% |
Price targets
Where 8 covering analysts think GSK trades over the next 12 months.
$59.58 +26.7% upside Strong Buy
Current$47.02 Low$50.00 Median$59.00 High$70.00 8 analysts
$50.00$70.00
Analyst rating Hold· 2.6/5 as of Oct 2, 2026
Social media sentiment mood +36.4%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
82°
Bullish
BearishNeutralBullish
Recent posts
SPRO Spero Therapeutics FDA approval and then drops? Cheaper buyout?
▲ 1 · 💬 1· ⚡ 0.5
it seems easy to get rich on the stock market
▲ 1 · 💬 5· ⚡ 0.5
AnaptysBio ($ANAB) - biotech with key upcoming price catalysts
▲ 1 · 💬 0· ⚡ 0.5
AnaptysBio ($ANAB)
▲ 1 · 💬 1· ⚡ 0.5
Spero Therapeutics Changing focus
▲ 1 · 💬 1· ⚡ 0.4
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
20 SEC filing reports analyzed · 7 bullish, 0 bearish, 1 mixed, 12 neutral · avg impact 3.8/10.
NEUTRAL6-K5/10
GSK announced an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) for
Sep 15, 2026
BULLISH6-K7/10
GSK announced positive overall survival data from the ARTEMIS-008 Phase III trial of Ris-Rez (risvut
Sep 14, 2026
BULLISH6-K7/10
GSK announced positive registrational data from the ARROS-1 trial evaluating Jideytro (zidesamtinib)
Sep 14, 2026
NEUTRAL6-K1/10
This 6-K filing reports routine acquisitions of GSK ordinary shares by multiple PDMRs (senior execut
Sep 11, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)
Phase Phase 3 — COMPLETED
Sep 25, 2026
short_volume
Short Volume: GSK — 62.6% short (0.6M / 1.0M)
Short: 603,019 | Exempt: 0 | TRF Vol: 964,053 | Short Ratio: 62.6% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: GSK — 56.2% short (0.5M / 1.0M)
Short: 534,442 | Exempt: 988 | TRF Vol: 950,509 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: GSK — 63.6% short (0.7M / 1.1M)
Short: 677,078 | Exempt: 376 | TRF Vol: 1,064,194 | Short Ratio: 63.6% | Off-exchange volume (dark pool + OTC)
Sep 22, 2026
short_volume
Short Volume: GSK — 65.1% short (0.9M / 1.4M)
Short: 882,366 | Exempt: 518 | TRF Vol: 1,356,417 | Short Ratio: 65.1% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.35 | $1.32–$1.39 | -7.2% | +0.5% | 1↑ 0↓ | $8.9B | 2 |
| Next Q | $0.79 | $0.76–$0.83 | 13.7% | -4.0% | 0↑ 1↓ | $9.0B | 2 |
| Current FY | $4.80 | $4.72–$4.88 | 1.8% | +0.1% | 0↑ 1↓ | $33.9B | 5 |
| Next FY | $5.02 | $4.85–$5.18 | 4.6% | +0.7% | 0↑ 2↓ | $35.5B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.351 | — |
| 7d ago | $1.344 | +0.007 |
| 30d ago | $1.344 | +0.007 |
| 60d ago | $1.414 | -0.063 |
| 90d ago | $1.445 | -0.095 |
Institutional ownership
Which big funds own GSK (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $14.5B total value (275,972,610 shares) as of 2026-Q2. Top holders: FMR, DODGE, Fisher. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| FMR LLC | 64,961,641 | $3.4B | 23.5% | — |
| DODGE & COX | 48,197,514 | $2.5B | 17.5% | — |
| Fisher Asset Management, LLC | 35,722,792 | $1.9B | 12.9% | — |
| PRIMECAP MANAGEMENT CO/CA/ | 25,182,068 | $1.3B | 9.1% | — |
| WELLINGTON MANAGEMENT GROUP LLP | 11,396,249 | $597.4M | 4.1% | — |
| MORGAN STANLEY | 7,657,562 | $401.4M | 2.8% | TRIM -30.6% |
| ROYAL BANK OF CANADA | 7,588,928 | $397.8M | 2.7% | — |
| GOLDMAN SACHS GROUP INC | 6,371,442 | $334.0M | 2.3% | TRIM -33.6% |
| STATE STREET CORP | 5,959,115 | $315.1M | 2.2% | — |
| BANK OF MONTREAL /CAN/ | 4,042,863 | $211.9M | 1.5% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MORGAN STANLEY | TRIM | 11,030,651 | 7,657,562 | -30.6% | $401.4M |
| GOLDMAN SACHS GROUP INC | TRIM | 9,589,114 | 6,371,442 | -33.6% | $334.0M |
| UBS Group AG | ADD | 2,084,235 | 2,806,205 | +34.6% | $147.1M |
| Point72 Asset Management, L.P. | NEW | — | 2,652,881 | — | $139.1M |
| JPMORGAN CHASE & CO | DOUBLED | 578,828 | 2,085,014 | +260.2% | $110.1M |
| SEI INVESTMENTS CO | TRIM | 2,286,880 | 1,250,431 | -45.3% | $65.5M |
| Qube Research & Technologies Ltd | ADD | 548,222 | 1,078,767 | +96.8% | $56.5M |
| D. E. Shaw & Co., Inc. | NEW | — | 1,019,449 | — | $53.4M |
| NewEdge Advisors, LLC | DOUBLED | 101,137 | 953,574 | +842.9% | $50.0M |
| VAN ECK ASSOCIATES CORP | TRIM | 1,066,648 | 787,508 | -26.2% | $41.3M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for GSK.
Shares short
14,652,083
Settlement Sep 15, 2026
Change vs prior
+8.2%
Semi-monthly cycle
Days to cover
5.5
At avg daily volume
Of shares outstanding
≈0.7%
Estimate — not % of float
All GSK filing & press-release reports (42)
- 6-K reportSep 15, 2026
- 6-K reportSep 14, 2026
- 6-K reportSep 14, 2026
- 6-K reportSep 11, 2026
- 6-K reportSep 10, 2026
- 6-K reportSep 10, 2026
- 6-K reportSep 1, 2026
- 6-K reportSep 1, 2026
- 6-K reportAug 26, 2026
- 6-K reportAug 24, 2026
- 6-K reportAug 24, 2026
- 6-K reportAug 24, 2026
- 6-K reportAug 18, 2026
- 6-K reportAug 11, 2026
- 6-K reportJul 30, 2026
- 6-K reportJul 28, 2026
- 6-K reportJul 28, 2026
- 6-K reportJul 28, 2026
- 6-K reportJul 22, 2026
- 6-K reportJul 17, 2026
- 6-K reportJul 17, 2026
- 6-K reportJul 16, 2026
- 6-K reportJul 15, 2026
- 6-K reportJul 14, 2026
- 6-K reportJul 13, 2026
- 6-K reportJul 13, 2026
- 6-K reportJul 10, 2026
- 6-K reportJul 9, 2026
- 6-K reportJul 9, 2026
- COURT-RULING reportJul 3, 2026
- 6-K reportJul 1, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 29, 2026
- 6-K reportJun 17, 2026
- COURT-RULING reportJun 17, 2026
- 6-K reportJun 15, 2026
- 6-K reportJun 12, 2026
- 6-K reportJun 11, 2026
- COURT-RULING reportJun 9, 2026
- 6-K reportApr 13, 2026
- 6-K reportMar 30, 2026
- 6-K reportMar 26, 2026